Across TCGA pan-cancer cohorts, NUDT19 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NUDT19 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NUDT19 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NUDT19 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where NUDT19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.567	0.894	<.001	45	view →
CCRCC	OS	Median	III,IV	0.202	0.985	.007	15	view →
PDAC	DFS	Tertile	IV	0.217	0.749	.024	6	view →
LSCC	OS	Median	II,III,IV	0.784	0.932	.020	5	view →
HNSC	DFS	Tertile	IV	0.807	0.529	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: NUDT19 tumor-vs-normal RNA expression · all NUDT19 data types